BeOne Medicines has announced a $300 million expansion of its manufacturing and research campus at the Princeton West Innovation Campus in Hopewell, New Jersey, adding small molecule production capabilities to a site that has until now focused on biologics manufacturing.
The investment increases the company’s total commitment to the Hopewell campus to more than $1 billion and raises its overall U.S. manufacturing investment above the same threshold. The project is expected to create 120 new manufacturing jobs and will expand the site’s role in supporting both commercial and clinical-stage production activities.
According to the company, the development will include construction of a new three-story building covering 145,000 square feet. The facility will be used for drug product manufacturing and packaging and will be located adjacent to BeOne’s existing operations in Hopewell. Once completed, the overall footprint of the campus is expected to reach 545,000 square feet.
In addition to manufacturing space, the new building will contain quality control laboratories, office facilities and areas reserved for future expansion. BeOne said some of this capacity may also be available to support strategic collaborations with partners.
The Hopewell campus serves as both a manufacturing center and the company’s research and development hub in the United States. Opened in July 2024, the site was initially backed by an $800 million investment. The latest expansion is scheduled to become fully operational by 2029, when the company expects total employment at the location to reach 240 workers following the launch of small molecule operations.
The new manufacturing capabilities are intended to support BeOne’s hematology portfolio. The company said the addition of small molecule production will support products in that portfolio, including the BTK inhibitor Brukinsa and the investigational BTK degrader tacabrutideg. The Hopewell site currently has biologics production capabilities, with the expansion adding small molecule manufacturing capacity.
Hopewell is currently BeOne’s only manufacturing facility in the United States and one of three manufacturing sites operated by the company globally. The other two facilities are located in Guangzhou and Suzhou, China.
Commenting on the announcement, Aaron Rosenberg, BeOne’s chief financial officer, said, “Today’s announcement reflects BeOne’s commitment to strengthening U.S. manufacturing and expanding access to innovative medicines for patients with cancer.”
Rosenberg also said that federal tax policies aimed at encouraging biopharmaceutical manufacturing investment, along with New Jersey state initiatives supporting advanced manufacturing and job creation, have helped create conditions that support long-term growth.
BeOne noted the significance of its U.S. operations within its broader global business. Of the company’s approximately 12,000 employees worldwide, more than 2,000 are based in the United States. The company also stated that it generated nearly $2 billion in direct economic impact in the U.S. during 2025 and invested roughly $1 billion in domestic research and development activities that year.
Headquartered in Switzerland, BeOne said the latest expansion will further increase domestic production capacity. The addition of small molecule manufacturing capacity at the Hopewell campus is intended to support the company’s hematology efforts and brings total investment in the site to more than $1 billion.
BeOne has announced a $300 million investment to expand its New Jersey campus by adding advanced small molecule manufacturing capabilities. The investment reflects BeOne’s long-term strategy to strengthen its global production network, accelerate drug development, and enhance supply chain resilience. By increasing domestic manufacturing capacity, BeOne aims to support future commercial products while improving operational flexibility for its growing pharmaceutical portfolio.
Future Growth Plans for BeOne
The new investment will enable BeOne to establish state-of-the-art facilities dedicated to the production of small molecule medicines. These facilities are expected to incorporate advanced manufacturing technologies that improve efficiency, product quality, and production scalability.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
